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Abstract 
Background:  Oral submucous fibrosis (OSF) is a chronic, insidious disease characterized by 
progressive submucosal fibrosis of the oral cavity and the oropharynx. People affected by this 
disease mostly live in south Asia, but migrants from these countries to the USA and Europe may 
present with OSF. 
Purpose: We provide a historical background of the disease and the objective of this review is to 
update the current knowledge on the aetiology and aetiopathogenesis of OSF.  
Introduction 
Oral submucous fibrosis (OSF) is a chronic, insidious disease that affects the lamina propria of 
the oral mucosa and as the disease advances it involves tissues deeper in the submucosa of the 
oral cavity with resulting loss of fibroelasticity.1 OSF is within a group of  conditions that is 
classified under oral potentially malignant disorders 2. The disease manifests with blanching and 
stiffening of the oral mucosa leading to limitation in opening of the mouth. The presence of 
fibrous bands in lips, cheeks and soft palate is a hallmark of the disease. The disease is 
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histopathologically characterized by fibrosis that affects oral cavity, pharynx and upper third of 
the oesophagus. The prevalence of the disease is on the rise as a result of increased use of 
commercially prepared areca nut preparations in India.3  
 
Historical perspective 
OSF was first described by Schwartz in 1952 4 among five Indian females living in Kenya and he 
coined the term Atrophia idiopathica (trophica) mucosae oris.  Several other descriptive terms 
have been given by subsequent authors, including idiopathic scleroderma of the mouth, 
idiopathic palatal fibrosis, and sclerosing stomatitis. 5-7 Lal highlighted the diffuse nature of OSF5 
and the condition is no longer considered “idiopathic”. 
 
Our understanding of oral submucous fibrosis has evolved as a clinico-pathological entity over 
many decades. Jens Pindborg - a Danish pathologist - in his various and extensive travels as a 
WHO consultant to south and far east of globe in search of tropical diseases,  comprehensively 
described various facets of the condition. Pindborg with several Indian colleagues initiated an 
extensive study on the natural history of oral precancer in a rural population of India. Their 
journey began at Tata Institute of Fundamental Research (TIFR) in Mumbai with several field 
stations spread across India. At the time OSF was an enigma to both Jens and to the TIFR team. 
Field studies planned by Jens and undertaken by the TIFR team led to a breathtaking study that 
comprised of examining over 200,000 Indian villagers over a span of 30 years. A great clinician 
and a scientist, his sincerity to work in the villages of India with no basic amenities available, 
showed the man’s motivation and caliber of commitment.  Pindborg’s  art of observations and 
determined  follow up of his observations on this condition over 2 decades lead to several logical 
conclusions including the premalignant nature of OSF. Supported by the statistical parlance of 
Prakash Gupta the team  led by Fali S. Mehta and Jens Pindborg published their findings in over 
30 scientific papers,  describing the epidemiology and clinicopathologic aspects of OSF, as we 
know of today 8-15. 
 
Aetiology  
Until about a decade and half ago the aetiology of the disease was thought to be multifactorial 
and several agents have been reported, including local irritants (chilies), nutritional deficiency, 
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and auto-immune disease. However, more recent studies have confirmed areca nut as the major 
(and the only) risk factor of oral submucous fibrosis, among people who probably have a genetic 
predisposition to the disease. Sufficient evidence on its etiological role based on epidemiological, 
animal and in vitro studies has been assembled by the International Agency for Research on 
Cancer and is elegantly presented in several of their monographs 16-18. Areca nut (Fig 1) may be 
consumed alone or as an ingredient of betel quid. The terminology of various areca consumption 
habits described by Gupta and Warnaklasuriya 19 and IARC (2004)17 is listed in Table 1. The 
role of other ingredients in betel quid (leaf, slaked lime or tobacco) as causative of OSF has not 
been established.17 In several cross sectional studies from Taiwan where betel quid is used 
without added tobacco, significant association of areca/ betel quid use with OSF were found. 18  
 
In 1995, Murti et al published a review on the aetiology of OSF 20 and the topic was discussed 
during an expert symposium in London 21. At the time reported ecological observations pointed 
towards a possible hypothesis of an association of areca nut with OSF, but the data was weak for 
inferring a causal relationship.  Over the past 15 years additional data have emerged crystalising 
our understating on the aetiological role of areca nut in causing OSF. However, only an 
estimated 1-2% of the population who have an areca nut chewing habit may develop the disease. 
This suggests a possible genetic predisposition in the affected people (see later). 
 
In this review we update the current evidence from primary studies that lead to the IARC’s 
conclusions. Eligible studies were identified from the Monographs published by IARC17,18 and 
more recent literature. A narrative review is present here. 
 
Epidemiological studies 
OSF is predominantly encountered in people of South and South East Asia (Fig 2) or among the 
diaspora arising from these countries.   The evidence on the role of areca nut use increasing the 
risk for development of OSF is based on case reports, case-series studies, prospective cohort 
studies, and several case-control studies conducted in India, Pakistan Sri Lanka and Taiwan. The 
relative risk estimates for OSF reported in case-control studies from these 4 countries ranged 
from 1.8-172 (Table 2). Large confidence intervals noted in many studies are due to “small cell 
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sizes” in the 2x2 tables  in these studies. A summary outcome of these studies by each country is 
presented below: 
 
India: Five case-control studies from India conducted in Bhavanagar, Nagpur, Kerala, Patna and 
Chennai provide the relative risk estimates on the use of areca nut 22-26. Sinor et al provided the 
first convincing epidemiological study by comparing chewing habits of mawa and bêtel quid of 
60 OSF cases with 60 controls. The reported relative risks were 109.6 for all forms of areca nut 
chewing, commonly in the form of mawa, primary ingredient of which was areca nut. 
Subsequent studies from other parts of India (Dharwad) have confirmed these findings 27. 
Hazarey et al 28 reported significant differences in chewing habits between men and women  
(males chewing Gutkha, mawa and kharra and women chewing exclusive areca nut). Men were 
reported to develop the disease at a younger age.  
 
Pakistan: Only case-control study from Pakistan to evaluate the etiology of OSF was conducted 
in Karachi by Maher et al 29. They reported various chewing habits of 157 subjects diagnosed 
with OSF, and estimated RR by comparison with 157 hospital controls. This study estimated a 
high relative risk of 154 (95% CI 34-693) for areca nut alone users in this Karachi population. 
 
Sri Lanka:  One study conducted in a hospital setting (74 cases and 74 controls) confirmed a 
strong association of OSF with Betel Quid (BQ) chewing (OR = 171.83, 95% CI: 36.35–812.25). 
In Sri Lanka, areca nut is the primary ingredient of BQ. 30 The numbers chewing areca nut alone 
were meager, and the study did not find any significant risk. 
 
Taiwan: The significance of Taiwanese studies that add weight to areca nut as causative relates 
to the use of betel quid without any added tobacco by this population. Three forms of betel quid 
are used in Taiwan, all with areca nut as the main ingredient: betel quid, lao-hwa quid and stem 
quid. 31 All reported studies have indicated a significant association of OSF with areca nut or 
betel quid use. 31-36 
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The percentage of subjects with an areca nut habit was close to 100% among OSF cases in these 
observational studies. Case reports that describe fibrosis in non chewers, probably had falsified 
habit histories or fibrosis arising from other inflammatory disorders . 
 
There are also case-series reports among Indian migrants living in other countries particularly 
South Africa and the UK which indicates continuation of their areca nut chewing habit following 
migration 37,38  Few cases are however, reported among citizens of non-Indian origin. 39,40 
 
 
 
Dose response 
In toxicological studies it is necessary to demonstrate a dose response to confirm a causal effect 
of an agent under study. In the case of areca nut and betel quid several studies have demonstrated 
a dose response by examining the frequency and the duration of use. Most studies conducted so 
far show an increased relative risk with longer duration of use and higher daily consumption 
(Table 3). There is also clear evidence indicating that with an upsurge of manufactured products 
containing areca nut (pan masala and Gutka – see Table 1) arriving in markets in India the 
disease prevalence has increased significantly 3 and OSF  is being diagnosed at younger ages. 41 
This could be due to a rapid development of the disease or starting the chewing habit  at a very 
early age.  
 
Experimental animal studies 
Few studies have reported in-vivo data on the ability of the areca nut extracts to produce OSF in 
animal models., Huang, Ling and Wu 43 described a rat model of OSF in Hunan Medical 
University, China and earlier in-vivo experiments of Khrime et al 44 showed histopathological 
findings akin to OSF induced by pan masala on the rat mucosa. The characterizations of these 
models were not complete and the experimental evidence was neither convincing nor 
reproducible. The relevance of a particular animal model to a human disease rests on its ability to 
parallel the biological changes that characterize the disease in humans 
Perera et al 45 described an OSF animal model in female albino mice of BALB/c strain. They 
applied an aqueous areca nut extract prepared from fresh, mature endosperms of Areca catechu 
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by dissolving nuts in 0.9% normal saline (50 mM NaCl) on the buccal mucosae of mice (n=40) 
for 600 days. Their study showed fibrosis of treated buccal mucosa as a continuous process 
occurring in the subepithelial buccal mucosal tissues of treated mice. (Fig 3) The amorphous 
areas confirmed by van Gieson and Masson’s trichrome stains, was an indication of early 
hyalinization, reflected the presence of young collagen or altered ground substance or both. The 
findings confirming the excessive deposition of collagen in the treated animals reported by them 
did bear a close similarity to human OSF. 
In this in-vivo mouse model the effects of areca nut extract on epithelial thickness leading to 
atrophy, connective tissue fibrosis, progressive reduction of fibroblasts, and inflammatory 
changes, were closely similar to that found in human OSF 46. The experimental data presented by 
Perera et al, further supports areca nut contributing to the causation of OSF. 
 
In vitro studies 
Several investigators have studied the effects of constituents of  areca nut , such as arecolene and 
arecaidine on oral fibroblasts in vitro in order to provide corroboratory evidence of its cause and 
effect.  The addition of arecoline and arecaidine has shown stimulatory effects on fibroblasts in 
culture 46-48. In a later study, fibroblasts when subjected to different concentrations of aqueous 
concentrations of raw or boiled areca nut showed morphological alterations 49.  In other in vitro 
studies fibroblasts from OSF specimens showed a more than a 1.5 fold increase in production of 
collagen compared with fibroblasts from age and sex matched and passage-matched normal 
controls 50. 
 
Summary on aetiology 
A comprehensive evaluation of data reported from epidemiological, in vivo and in vitro studies 
led the IARC (2004)17 to confirm the etiological role of areca nut as the causative agent of OSF. 
It is extremely uncommon to find signs of OSF in a non areca nut chewer. Few case reports that 
describe OSF in  never users appear to be misclassification of the disorder due to finding of 
sclerotic fibrous bands rarely encountered in other chronic inflammatory disorders (eg ulcerative 
lichen planus or o-GVHD). 
 
Aetiopathogenesis 
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Although the disease was described in 1950s, its pathogenesis has not been clear until recently. 
Three previous reviews 51-53 had undertaken to critically examine the scientific data available on 
the pathogenesis of OSF published till 2013. This review updates these research findings  
Several mechanisms and biological pathways have been proposed for the pathogenesis of the 
disorder, all based on the constituents of areca nut and genetic susceptibility to the disease. The 
flow chart shown below illustrates the possible biochemical and molecular events known in the 
pathogenesis of OSF (Figure ). 
 
Mechanisms of pathogenesis of oral submucous fibrosis 
Changes in the extracellular matrix 
Areca nut alkaloid, arecoline is now identified as the principal causative factor for OSF. 
Arecoline appears to be involved in the pathogenesis of OSF causing fibroblastic proliferation 
and increased collagen formation.  
Involvement of connective tissue growth factor (CTGF) in fibrosis in many human tissues is well 
established. CTGF is only produced by hepatic stellate and kidney mesangial cells in adults 
under normal conditions,  Deng et al 54 have shown expression of CTGF in OSF fibroblasts and 
endothelial cells in all the OSF cases included in their study.   Their in vitro data have shown that 
arecoline stimulated CTGF production in buccal mucosal fibroblasts through generation of 
reactive oxygen species (ROS), and by the activation of NF – kappa B, JNK and p38 MAPK 
pathways. It is also known that NF- kappa B, JNK and p38 are strongly activated by ROS.  
Significance of ROS in the pathogenesis and malignant transformation of OSF. 55 has been  
highlighted.55 
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Arecoline influences deposition of extra cellular matrix (ECM) by increasing the production of 
TIMP-1 and the effect is enhanced when fibroblasts are co cultured with keratinocytes.56 This 
data suggested that an interaction of oral keratinocytes and fibroblasts may play an important 
role in the pathogenesis of OSF.56 Interaction of arecoline and keratinocytes may induce the 
differentiation of myofibroblasts from fibroblasts.57  Another study proposed that areca alkaloids 
induce buccal mucosal fibroblast contraction and persistent fibroblast contraction may induce 
fibrotic process in OSF.58  The fact that arecoline influences ECM was further supported by the 
evidence for Transglutaminase-2 (TGM – 2) over expression in OSF and its regulation by 
arecoline. TGM – 2 stabilizes ECM protein by cross linking and has been implicated in several 
fibrotic disorders.59 
Reduced vascularity is another hallmark of OSF. In order to highlight this aspect, effects of 
arecoline on endothelial cells have been investigated. It is reported that at concentrations of 0.4 
and 0.8 mM, arecoline induces cytotoxicity and also G2/M cell cycle arrest and increase sub - G0 
/ G1 population, a hall mark of apoptosis. Further it is observed that prolonged exposure to 
arecoline (0.1mM) significantly suppress endothelial cell proliferation. Also the exposure to>0.2 
mM arecoline decreases the proportion of endothelial cells residing in S phase but increases the 
cells arresting in G2/M phase. These findings suggest that the anti-proliferative and cytotoxic 
effects of arecoline are possibly associated with the alteration of specific cell cycle regulatory 
proteins. Therefore, it is reasonable to suggest that the endothelial damage leading to impairment 
of vascular function contribute to the pathogenesis of OSF60 These findings explain the 
decreased vascularity that is observed in histological sections, especially with the progression the 
disease. Loss of vascularity may lead to atrophy of the epithelium and the resulting hypoxic 
environment may predispose the tissue to carcinogenesis.   
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In addition to arecoline, arecanut contains more active components including other alkaloids 
(arecaidine, guvacine, guvacoline and arecolinidine), polyphenols (catechin, flavanoids, flavan-
3:4-diols, leucocyanidins, hexahydroxyflavans and tannins) and trace elements (sodium, 
magnesium, chlorine calcium, vanadium, manganese, copper and bromine). Polyphenols of 
arecanut such as flavanoid, catechin and tannins cause collagen fibers to crosslink, and thereby 
make them less susceptible to collagenase degradation. The resulting decrease in collagen 
breakdown in turn leads to increased fibrosis which is the mainstay of the pathogenesis of 
OSF.61. 
 
Matrix metalloproteinases and Tissue inhibitors of matrix metalloproteinases (MMPs and 
TIMPs) 
Accurate and balanced collagen metabolism is essential to maintain the normal integrity of 
connective tissue. Equilibrium between two enzyme groups, MMPs and TIMPs is mandatory to 
achieve the above. In OSF the equilibrium between MMPs and TIMP is disturbed in such a 
manner that it ultimately results in increased deposition of ECM.. We demonstrated an 
attenuated expression of MMP1 in OSF tissues compared with normal oral mucosa. 62 Since 
MMP-1, is the main human enzyme that degrades fibrillar collagen, its downregulation may lead 
to a reduction in collagen degradation. In addition, stronger intensity of TIMP-1 in fibroblasts of 
OSF than in normal oral mucosa suggested  improper regulation of proteolytic equilibrium as 
one of the main factors responsible for the excessive fibrosis in OSF.62 The fibroblasts in OSF 
have a reduced replicative life span as they accumulate senescent cells during the progression of 
the disease. This is due to the increased amount of ROS and DNA double strand breaks (DDBs) 
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produced intrinsically by damaged mitochondria. TIMP -1 & 2 are increased in fibroblast 
cultures of OSF relative to normal and non-diseased pan user controls. Following the 
introduction of unrepairable DDBs into normal cultured oral fibroblasts TIMP-1 and TIMP-2 
secretion increased within 5 days. , Furthermore, TIMP-1 production is enhanced when 
fibroblasts are co cultured with keratinocytes pretreated by arecoline. 63,64 This highlights  an  
interaction of oral keratinocytes and fibroblasts in the pathogenesis of OSF. Endogenous 
collagenase activity in OSF tissues is shown to be 3-5 folds less than that in normal oral mucosa, 
which may also be responsible for collagen accumulation.64 Our data have been reproduced in a 
recent study that has revealed a decrease in intensity of MMP-1 expression in the epithelium and 
connective tissue of buccal mucosal tissue of OSF compared with  normal tissue.65 
The above studies highlight the evidence for imbalance between MMPs and TIMPs via different 
mechanisms leading to accumulation of collagen in OSF. Further, the interaction between 
keratinocytes and fibroblasts is important in pathogenesis suggesting that OSF is an epithelium 
driven connective tissue disease.. 
Copper and related structural changes of collagen 
The role of copper in the pathogenesis of OSF has been raised as a result of the discovery of a 
high copper content in arecanut.66 Copper dependant enzyme lysyl oxidase is critical for collagen 
cross linking and organization of ECM.67  Salivary copper is found to be higher in arecanut 
chewers. This finding indicates that soluble copper found in arecanut is released into the oral 
environment and its buccal absorption may contribute to fibrosis of oral tissues where copper is 
deposited.  This observation suggested a possible local effect of copper in the aetiopathogenesis 
of OSF.68 Salivary copper levels appear to vary from mild OSF to severe cases.69 Serum copper 
levels in OSF is also raised suggesting a systemic effect and increase in serum copper level has 
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been shown with the advancement of the clinical stage.70,71  However, the effect of copper 
appears to be local in the context of OSF as there is no evidence to suggest that these patients 
demonstrate  any clinical evidence of systemic or organ fibrosis. 
Morphological features of ECM Remodelling in OSF  
Histopathological evidence shows  ECM remodeling with the progression of the disease. Stage-
specific alterations in ECM have been reported. 72  In the early stages of OSF over expression of 
tenascin, perlecan, fibronectin and collagen type III may be found  in the lamina propria and 
submucosa while extensive and irregular deposits of elastin were found around muscle fibres in 
the intermediate stage, together with the above molecules. In the advanced stage collagen type I 
appears to dominate the ECM. Their gene expression levels were varied with the progression of 
fibrosis. This pattern of ECM remodeling steps in OSF is similar to normal granulation tissue 
formation and maturation process. Difficulty in opening the mouth may be related to loss of 
various ECM molecules such as elastin and replacement of muscle by collagen type I.72 
Heat shock protein (HSP) 47, a known collagen specific molecular chaperone involved in the 
processing and/or secretion of procollagen is significantly upregulated in OSF. Treating 
fibroblast with arecoline was found to elevate HSP 47 m-RNA expression in a dose dependent 
manner through MEK, PI3K and COX-2 signal transduction pathways.73 Cystatin C, a non 
glycosylated basic protein is increased in a variety of fibrotic diseases. Cystatin C was found to 
be upregulated both at m – RNA and protein levels in OSF and arecoline is responsible for this 
enhancement in a dose dependent manner.74 Malondialdehyde (MDA) is a lipid peroxidation end 
product with the potential to stimulate fibroblasts and to increase collagen production. MDA is 
significantly elevated as the grading of OSF progressed. 75 
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Inflammatory cytokines and Growth factors 
Upregulation of various cytokines namely, TGF β1, TGF β1p, THBS1, SPP1, TIG1, TGM2 and 
CTGF and down regulation of BMP7 which is a known negative modulator of fibrosis has been 
reported.76  TGF β is implicated as one of the main triggers for the increased collagen production 
and decreased matrix degradation pathways in OSF.52,77 It has been shown that the expression of 
TGF-β1 was significantly upregulated within the connective tissue  of OSF compared to normal 
mucosa.62 Treatment of cells with arecanut water extract consisting of polyphenols and alkaloids, 
has shown that 64% of the differentially regulated genes found in test samples matches with the 
TGF β induced gene expression profile.78 This suggests that arecoline induces TGF β in  
keratinocytes  and furthermore this is observed only in  keratinocytes  but not in human gingival 
fibroblast cells, indicating that  keratinocytes could be the source of TGF β in OSF. Further, 
studies have revealed that keratinocytes  secrete TGF β through αvβ6 integrin expression.79  
Same authors have illustrated loss of  TGF β expression  using the drug tropicamide that blocks 
αvβ6 integrin confirming that OSF is an epithelial driven connective tissue disease. 79 
Phosphorylation of SMAD -2 was observed following treatment of keratinocytes by catechin, 
tannin and alkaloids, hence the authors state that arecanut mediated activation of p-SMAD - 2 
involves upregulation and activation of TGF β.78 CTGF/CCN2 and COX-2 were found to be 
over expressed in OSF. The CCN2 synthesis in buccal mucosal fibroblasts is stimulated by TGF 
β1 and this reaction is mediated via ALK5, JNK and p38 MAPK pathways. Epigallocatechin-3-
gallate (EGCG) in turn can completely block TGF β1 induced CCN2 synthesis by suppressing 
JNK and p38 in buccal mucosal fibroblasts, which may be useful in controlling OSF.77 Loss of 
adipose tissue in OSF was found to be due the ability of TGF β to cause lipodystrophy. Level of 
TGF β secretion is more during the early course of the disease.80 b-FGF is increased in 
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fibroblasts and in endothelial cells in early disease, and in advanced fibrosis b-FGF expression 
was noted more in stroma.81 IGF-1 expression is significantly upregulated in OSF both at m-
RNA and protein levels and arecoline had been responsible for this elevation in a dose dependant 
manner.82 Recently it was reported that the homozygous wild genotype TNF-α2 was significantly 
associated with an increased risk of OSF and the mutant allele TNF-α2 is about 7 times more 
efficient in promoter function than the wild allele. Accordingly, TNF-may play a role in 
pathogenesis of OSF through modulation of collagen metabolism.83 With the available literature 
on growth factors and cytokines, TGF β appears to be the main mediator of the disease and 
others such as TNF-α, IGF-1, b-FGF and CTGF may contribute to continuous accumulation of 
collagen with activation of signaling pathways such as ALK5, JNK, SMAD and p38 MAPK. 
These molecules and pathways can be the target areas for new treatment strategies. 
 
Epithelial–mesenchymal transition (EMT) 
Epithelial–mesenchymal transition (EMT) has gained significant attention due to its  implication 
in cancer and fibrosis. Cell injury caused by areca nut extract produces ROS which in turn 
triggers both MAPK and NF-κB pathways involved in EMT of OSF. Thereby exposure to areca 
nut extract causes alterations of normal keratinocyte morphology and induces the cell cycle 
arrest at G1/S phase and the senescence-associated phenotypes. Keratinocytes secrete a variety 
of inflammatory mediators such as PGE2, IL-6, TNF–α and most importantly TGF-β, in 
response to injury. Hif-1 α enhances the EMT in vitro and promotes fibrogenesis by increasing 
expression of extracellular matrix–modifying factors and lysyl oxidase genes. Further, it is 
evident that both ROS and HIF-α were necessary for hypoxia-induced TGF-β1 upregulation. In 
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OSF  a possible relationship between Hif-1 α, ROS and EMT has been revealed  as we have 
shown an upregulation of Hif-1 α 84 in OSF  and also production of ROS by arecoline treatment.  
 In summary the above events show possible EMT in OSF leading to fibrosis. Potentially, the 
transformed epithelial cell may proliferate to expand the fibroblast population, undergo 
apoptosis, or revert back to epithelial type. The fact that the transformed cell is able to 
dedifferentiate back to epithelial form directs future research into a novel path as it hints towards 
a possibility of reversing the disease process.85  
 
Molecules in cell cycle control and OSF 
 
There are few studies performed to find out the effects of cell cycle regulation and pathogenesis 
of OSF. ROS generated by arecoline may cause cell cycle arrest at the G1/G0 phase in human 
keratinocyte cells without affecting the expression of p21/Cip1. Further, oxidative stress may 
induce epithelial cell death without eliciting apoptosis at higher arecoline concentration. 
However, sub-lethal concentrations of arecoline upregulated the expression of several stress 
responsive genes namely; heme oxygenase-1, ferritin light chain, glucose-6-phosphate 
dehydrogenase, glutamate-cysteine ligase catalytic subunit and glutathione reductase.86  Similar 
study reported that 0.01-0.04mM arecoline caused late-S and G2/M phase cell cycle arrest in 
human KB epithelial cells. A decrease in cdc2 and Cyclin B1 protein levels and increasing p21 
were identified in gingival keratinocytes by Western blot analysis. It is also revealed that 
inhibition of KB epithelial cell growth in a dose and time dependant manner and a reduction in 
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cell number with higher arecoline concentration. Further increase in arecoline concentration has 
induced both cell necrosis and apoptosis.87 
 
 
Genetic polymorphisms predisposing to OSF 
 
There are estimated to be over 600 million areca nut chewers worldwide 19. However, only 1-2% 
of areca nut chewers may develop the disease. This suggests a possible genetic predisposition in 
the affected people. Rapid development of OSF in young adults or even children reported in 
clinical case reports 42 further adds weight to this hypothesis. HLA typing has shown certain 
HLA antigens with a high significantly raised frequency in OSF patients.. 
 
Although the exact mechanisms are not clear, various chromosomal, genetic and molecular 
alterations are associated with the pathogenesis of OSF.88 A study using Oligonucleotide 
microarray has shown 716 genes upregulated and 149 genes were downregulated in OSF. It is 
identified that genes are involved in immune response, inflammatory response and EMT induced 
by TGF β signaling pathway namely SFRP4. THBS1, MMP2, ZO-1.89 In another study, 
differentially expressed genes in OSF had been analyzed using bio informatic tools and the genes 
were located on chromosome 1,2,5,6,7,11 and 12. Gene ontology (GO) classification identified  
these genes to be related to cellular component sub groups associated with extra cellular matrix, 
cytoskeleton and cell membrane and also biological process subgroups associated with protein 
binding, signal transducer activity, immune and defense responses. 90  
Polymorphisms of various genes may also contribute to an increased susceptibility to OSF. 
Polymorphism of Cytochrome P450 3A gene family is considered as a major determinant of 
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inter-individual variability in chemical pharmacokinetics. Cytochrome P450 had been identified 
as a genetic biomarker for susceptibility to develop OSF. This may be helpful in identifying  
high risk individuals according to the genetic polymorphisms in some exclusive regions of the 
Cytochrome P450 3A, P4501A1 and CYP2E1 genes.91,92 Another study revealed the fact that 
CYP1A1 (m1) genotype and (m2) genotype singly acts as a protective factor but in the absence 
of GSTM1 and/or GSTT1 gene significantly alters risk towards the disease.93 A few genes 
related to the pathway of CYP metabolism such as CYP2B6, CYP2C18, CYP2F1, CYP3A5, 
microsomal glutathione S-transferase 2 (MGST2), alcohol dehydrogenase (ADH), UDP 
glucuronosyl transferase 2B15 (UGT2B15), and ADH1C were found to be down regulated in all 
stages of OSF, thereby reducing the ability of CYP to metabolize and clear betel nut substances 
and contributing to the pathogenesis.94 Recently, genetic polymorphism of lysyl oxidase, was 
identified and LOX Arg158GIn appeared to be associated more in elderly OSF patients.67 
Polymorphisms of collagen-related genes on OSF risk had been investigated. A study focused on 
the single nucleotide polymorphisms (SNPs) of TGFβ -1 gene reported that polymorphism in 
5¢UTR C-T in TGF beta 1 gene associated with pro-angiogenic pathway  has a significant 
association with OSF.95 Association of SNP (-1171 5A->6A) in the MMP-3 promoter region 
with the 5A alleles has an increased risk for developing the disease96 while SNPs in the MMP-2 
and MMP-9 promoter region is not associated with susceptibility to OSF.97 Relationship between 
OSF and TNF-α genetic polymorphism (-308), was not confirmed as the genotype distribution of 
TNF-α (-308) genetic polymorphism show similar distribution among areca chewers and non-
areca-chewers.83 N-acetyltransferase 2 locus codes for an enzyme that catalyze acetylation of 
aromatic amines. Polymorphisms at this specific site can cause improper acetylation of the 
amines, leading to DNA adduct formation. It is suggested that these polymorphisms can increase 
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the risk of OSF in men if exposed to arecanut.98 It can be summarized that the available evidence 
support the theory of possible genetic predisposition to the disease.(Table 4) 
 
Conclusion 
Oral submucous fibrosis was first described over 50 years ago in Indian migrants to south Africa 
and in Indian subjects as an idiopathic disorder. Observational studies by Jen Pindborg 
characterized the potentially malignant  nature of this disorder. Oral submucous fibrosis is 
characterised by the accumulation of excessive ECM in the lamina propria, predominantly type 1 
collagen and other collagens. Recruitment and differentiation of fibroblasts from the 
mesenchymal stem cell compartment is a key event and leads to functioning fibrocytes that lay 
down collagen. In addition to fibroblasts, myofibroblasts and mast cells may participate in 
fibrogenesis , tissue repair, and angiogenesis and have been implicated in inducing fibrosis.  In 
this disease areca nut and probably continuous mechanical irritation act as external  mediators. 
Growth factors and cytokines (eg TGFb) are key pro-fibrotic factors. We present here a complex 
sequence of mechanisms that promote fibrosis of the oral mucosa. 
 
Acknowledgements: We thank Dr Dinesh Daftary (Mumbai, India) for helpful comments on life 
and works of late Jens Pindborg. Fig 1 is reproduced with kind permission from Editor-in- Chief 
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Legends to figures 
Figure 1. Forms of areca nut used in south Asia, pacific islands and China: (a) Ripe areca fruit 
(b) unripe areca fruit as  consumed in Taiwan (c) areca nut (endosperm of Areca fruit shown in 
(a) commonly consumed in south Asia  (d) areca husk used in mainland China (Reproduced with 
kind permission of J Inv Clin Dent; Reichart PA,  Warnakulasuriya S. Oral lichenoid contact lesions 
induced by areca nut and betel quid chewing: a mini review. J Investig Clin Dent.. 2012 Aug;3(3):163-6 
  Figure 2.  Global map showing areca nut consuming populations  
Figure 3. 300-day areca-treated buccal mucosa in albino mice of BALB/c strain. Markedly atrophic 
epithelium (green arrow), densely deposited oedematous collagen in the lamina propria, inflammatory 
exudate (yellow arrow), atrophy of the muscles (white arrow) and less vascular connective tissue are 
prominent (Reproduced with kind permission of John Wiley & Sons, Inc. J Sumeth Perera MW, 
Gunasinghe D, Perera PA, et al. Development of an in vivo mouse model to study oral 
submucous fibrosis. J Oral Pathol Med. 2007; 36:273-80). 
)  
Figure 4. Schematic diagram showing possible molecules and pathways involved in the 
pathogenesis of oral submucous fibrosis. 
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Table 1: GLOSSARY OF ARECA NUT & ITS PRODUCTS 
 
Areca catechu L.: see areca nut  
 
Areca fruit: fruit of the palm Areca catechu L. — see areca nut 
 
Areca nut: nut from the fruit of the Areca catechu L. (Palmaceae) tree, a palm native to 
South Asia. The fruit is green when unripe and orange-yellow in colour when ripe and 
is the size of a small egg. The nut (seed) is separated from the fibrous pericarp and 
used fresh or dried, or processed by roasting, sun drying, boiling, soaking in water or 
fermenting. The unripe green areca fruit may also be used. Synonyms include supari 
(in Hindi and other languages in India), puwak (Sri Lanka), gua (in Sylheti), mak 
(Thailand), pinang (Sarawak and Malaysia), daka (Papua New Guinea), pugua 
(Guam) and Kun-ywet (Myanmar). The term ‘areca’ is derived by the Portuguese from 
Malayalam atrekka and from the Tamil aakkay.  
 
Betel inflorescence: flower of the vine Piper betle L. 
 
Betel nut: the term ‘betel nut’, although commonly used in the scientific literature, has 
caused considerable confusion and should be avoided. The correct term is areca nut 
because betel vine and areca palm are different plants. 
 
Betel quid: usually prepared by smearing a betel leaf with slaked lime, to which 
pieces of areca nut are added. Catechu may be added. Crushed leaves of cured 
tobacco and flavouring agents may also be added. The ingredients are folded in the betel 
leaf and chewed. Known as paan in Hindi and other languages in India and buyo in the 
Philippines.  
Betel quid may be prepared differently in different parts of the world.  
 
Gutka: commercial preparation of areca nut and powdered tobacco, slaked lime, 
catechu and other ingredients. Also spelt gutkha. 
 
Lao-hwa quid: specific Taiwanese term for unripe areca nut split in half, with 
inflorescence of Piper betle L. inserted in the middle and slaked lime added 
 
Mawa: mixture of predominantly areca nut pieces with some tobacco and slaked lime 
 
Naswar: mixture of powdered tobacco, slaked lime and indigo. Popular in Afghanistan 
and Pakistan. Also spelt nasswar, niswar 
 
Paan: see betel quid. Also spelt pan 
Pan masala: commercial preparation containing 
 
Pan masala: commercial preparation containing areca nut, slaked lime, catechu and 
other ingredients, but without tobacco.  
 
Stem quid: specific Taiwanese name for betel quid consisting of unripe areca nut split 
in half, with stem of inflorescence inserted in the middle and slaked lime added 
 
Supari: see areca nut 
 
Tamol: fermented form of areca nut 
 
Zarda: tobacco leaf broken into small pieces and boiled in water with slaked lime and 
spices until evaporation, then dried and coloured with vegetable dyes; usually chewed 
mixed with areca nut and spices 
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Authors, 
study 
location, 
publication 
year, (ref  
number) 
 
Characteristics of 
cases 
Characteristics 
of controls 
Exposure 
categories 
Relative risk (95% CI) Adjustment for 
potential 
confounders 
Sinor et al 
Gujarat, India 
1990 (22) 
60 cases 60 controls Non chewers 
Areca nut or 
mawa 
1 
109.6 
 
Maher et al  
Karachi,  
1994 (29) 
 
 
157 cases 
Attending 
outpatient clinic 
157 controls 
Attending 
outpatient clinic 
for other reasons 
Non chewer 
Pan 
Pan + TOBACCO 
Areca nut 
1 
32 (6-177) 
64 (15-274) 
154 (34-693) 
 
Yang et al 
(2001) (31) 
312 participants 
(119) men, 193 
women)  
 
out of a source 
population of 
3623 in Mutan 
Country 
(aboriginal 
Community) 
Non chewer 
Areca/BQ 
chewer 
1.0 
1.8 (0.7-4.8) 
Adjusted for each 
other, age and 
gender 
Lee et al 
(2003) 
Kaohsiung 
1994-95  (33) 
 
125 histologically 
confirmed cases of 
OSF (93 men, 1 
woman) 
876 population 
controls (844 
men, 32 women) 
matched on age 
and sex 
Never chewed 
Former chewer 
Current chewer 
1 
12.1 (2.8-51.9) 
40.7 (16.0 -103.7) 
 
Adjusted for 
education and 
occupation 
Jacob et al 
(2004) Kerala, 
India  (24) 
170 Oral 
submucous fibrosis 
47 773 subjects 
with no oral 
mucosal 
disorders from 
the same 
screening study 
Non chewer 
Chewer (betel 
quid only) 
Chewer (betel 
quid with 
tobacco) 
1.00 
56.2 (21.8-144.8) 
 
73.0 (32.9- 162.2) 
 
Yang et al 
(2005) 
Mutan 
community, 
Taiwan  (32) 
62 subjects  
Detected by 
screening 
 
62  controls 
selected from 
the same 
screening 
programme 
Non-chewer 
Chewer (betel 
quid only) 
 
1.00 
4.51 (1.20-16.94) 
 
Non smoker 
Ranganathan 
et al (2004)  
Chennai 
South India 
(25) 
185 cases  185 hospital-
based controls 
Non chewer 
Chewer AN 
Chewer (pan 
Masala) 
1 
3.10 (0.83±11.65) 
81.50 (4.95-1341.12) 
 
Chung et al 
(2005) 
 Taiwan (34) 
17 cases 1075 subjects 
examined 
Non-chewer 
Areca quid 
1.00 
151.9 (19.1-999) 
Included smokers 
Ariyawardana 
et al (2006) 
Sri Lanka  (30) 
74 (61 men, 13 
women) 
Hospital-based 
74 (61 men, 13 
women) 
 
 
Non-chewer 
Areca nut 
Betel quid 
1.00 
11.79 (0.64–217.2) 
16.24  (5.8–44.8) 
Non Tobacco 
or alcohol 
consumption 
Chen et al 
(2006) 
Taiwan (26) 
23 cases of 
submucous fibrosis 
(among 113 
pathology archives) 
23 control and 
27 cases of non-
premalignant 
disorders 
Non-chewer 
Chewer (betel 
quid only) 
1.00 
4.2 (0.17-0.54) 
 
Ahmad et al 
(2006) 
Patna, India 
(26) 
157 Oral 
submucous fibrosis 
cases hospital 
based 
135 Hospital-
based controls 
with other 
diseases 
Areca nut only 
Pan masala 
Pan 
Gutka 
172.8 9 (15.87-723.27) 
138.21 (32.97- 629.34) 
41.5 (12.33-156.59) 
234.9 (67.17-900.330) 
 
Yen et al 
(2008) 
China, Taiwan 
(36) 
441 oral 
submucous fibrosis,  
8360 men 
Participating in a 
screening 
Occasional use 
+20 pieces/day 
1 
6.89 (4.96-9.58) 
Age, Education, 
occupation, 
smoking & 
alcohol drinking 
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Table 1: Epidemiological studies confirming the association of areca / betel quid use with 
oral sub mucous fibrosis in India, Pakistan, Sri Lanka and Taiwan (Adapted from IARC 
Monographs 2004, 2012). Large confidence intervals noted in many studies are due to “small 
cell sizes” in the 2x2 tables  in these studies. 
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Author, 
year , 
reference 
number 
Quids/day Odds ratio (95% 
CI) 
 Duration of 
chewing (years) 
Odds ratio (95% CI) 
Maher et al 
(1994) (29) 
0 
1-5 
6-10 
10+ 
1  
84 (20-360) 
246 (47-1278) 
100 (19-522) 
 0 
1-5 
6-10 
10+ 
1 
72 (17-316) 
137 (29-640) 
109 25-479) 
Yang et al  
(2001) (31) 
1-10 
11-20 
>21 
1.0 
1.2 (0.7-2.04) 
1.3 (0.7-2.2) 
 1-10 
11-20 
21-30 
>31 
1 
1.8  (0.7-4.8) 
2.4  (1.0-5.0) 
2.4  (1.1- 5.0) 
Lee et al 
(2003)  
(33) 
1-10 
11020 
>21 
31.4 (11.9-82.5) 
37.4 (12.6-110.4) 
53.5 (16.4-174.8) 
 1-10 
11-20 
>21 
30.9 (11.3-84.7) 
41.9 (14.1-124.9) 
39.3 (11.7-131.7) 
Yang et al 
(2005) (32) 
1-9 
10-29 
30+ 
3.66 (0.71-18.91) 
4.55 (1.16-17.84) 
10.34 (2.30-44.73) 
   
Yen et al 
(2008)  
(36) 
 
Occasional 
1-10 
11-20 
20+ 
1 
1.26 (0.91-1.74) 
3.88 (2.75-5.60) 
6.98 (4.96-9.58) 
   
 
Table 3: Dose response relationship of areca habits and OSF 
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Genetic Polymorphism Role  in pathogenesis of OSF Reference 
Cytochrome P450 
Cytochrome P450 3A, 
P4501A1 , CYP2E1 
CYP1A1 (m1) and (m2) 
genotypes 
A genetic biomarker for susceptibility to 
OSF  
Marks  high risk individuals 
Confirms protection 
     91 
     92 
     93 
Lysyl oxidase 
LOX Arg158Gin 
 
Associated more in elderly OSF patients 
 
     67 
TGFβ -1 
(single nucleotide 
polymorphism in  
5¢UTR C-T) 
 
Increased risk for developing OSF        95 
 
 
 
 
MMP-3 
(single nucleotide 
polymorphism in  
-1171 5A->6A) 
Increased risk for developing OSF      96 
TNF-α (-308) No  confirmed relationship with OSF      83 
N-acetyltransferase 2 locus Increased risk for developing OSF ( men 
only 
      98 
 
Table 4: Genetic polymorphisms predisposing to OSF or confirming protection 
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Statement of clinical relevance 
 
Oral submucous fibrosis remains unfamiliar to clinicians in the Americas and Europe. Knowledge of  
the aetiology of this disease helps to identify “high risk” individuals and understanding the 
aetiopathogenesis of OSF may  contribute to new research to develop targeted therapies. 
 
